Solid Biosciences Llc Stock Today
| SLDB Stock | USD 4.03 0.09 2.28% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Solid Biosciences is trading at 4.03 as of the 17th of February 2025, a 2.28 percent increase since the beginning of the trading day. The stock's open price was 3.94. Solid Biosciences has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 20th of October 2024 and ending today, the 17th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 26th of January 2018 | Category Healthcare | Classification Health Care |
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. Solid Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 39.95 M outstanding shares of which 2.65 M shares are at this time shorted by private and institutional investors with about 4.35 trading days to cover. More on Solid Biosciences LLC
Moving together with Solid Stock
Moving against Solid Stock
Solid Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Alexander Cumbo | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSolid Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Solid Biosciences' financial leverage. It provides some insight into what part of Solid Biosciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Solid Biosciences LLC (SLDB) is traded on NASDAQ Exchange in USA. It is located in 500 Rutherford Avenue, Charlestown, MA, United States, 02129 and employs 88 people. Solid Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 161.02 M. Solid Biosciences LLC conducts business under Biotechnology sector and is part of Health Care industry. The entity has 39.95 M outstanding shares of which 2.65 M shares are at this time shorted by private and institutional investors with about 4.35 trading days to cover.
Solid Biosciences LLC currently holds about 162.88 M in cash with (94.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.44.
Check Solid Biosciences Probability Of Bankruptcy
Ownership AllocationSolid Biosciences LLC shows a total of 39.95 Million outstanding shares. The majority of Solid Biosciences LLC outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Solid Biosciences to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Solid Biosciences LLC. Please pay attention to any change in the institutional holdings of Solid Biosciences LLC as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Solid Ownership Details
Solid Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Citadel Advisors Llc | 2024-09-30 | 920.5 K | |
| Geode Capital Management, Llc | 2024-09-30 | 504.9 K | |
| Monashee Investment Management Llc | 2024-09-30 | 485 K | |
| Silverarc Capital Management, Llc | 2024-09-30 | 457.7 K | |
| Point72 Asset Management, L.p. | 2024-09-30 | 443 K | |
| State Street Corp | 2024-09-30 | 441.5 K | |
| Walleye Trading Advisors, Llc | 2024-09-30 | 392.1 K | |
| Alyeska Investment Group, L.p. | 2024-09-30 | 346.4 K | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 264.1 K | |
| Perceptive Advisors Llc | 2024-09-30 | 6.9 M | |
| Ra Capital Management, Llc | 2024-09-30 | 4.3 M |
Solid Biosciences Historical Income Statement
Solid Stock Against Markets
Solid Biosciences Corporate Management
| Gabriel MD | Chief Officer | Profile | |
| Shuli MD | Head Development | Profile | |
| Paul Herzich | Chief Officer | Profile | |
| Caitlin Lowie | VP IR | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Solid Biosciences LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Solid Biosciences. If investors know Solid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Solid Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Solid Biosciences LLC is measured differently than its book value, which is the value of Solid that is recorded on the company's balance sheet. Investors also form their own opinion of Solid Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Solid Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Solid Biosciences' market value can be influenced by many factors that don't directly affect Solid Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Solid Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Solid Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Solid Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.